1-3 of 3
Piera Angelillo
Close
Sort by
Journal Articles

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma

Andrés J. M. Ferreri, Piera Angelillo, Federico Erbella, Chiara Cattaneo, Luisa Verga, Arben Lleshi, Bernardino Allione, Maurilio Ponzoni, Fabio Facchetti, Chiara Pagani, Marco Foppoli, Lorenza Pecciarini, Marianna Sassone, Sara Steffanoni, Elena Flospergher, Giuseppe Rossi, Michele Spina, Alessandro Re
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5811–5820.
https://doi.org/10.1182/bloodadvances.2022007475
Published: 2022
Journal Articles

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial

Lydia Scarfò, Silvia Ferrari, Anna Maria Frustaci, Monica Tani, Alessia Bari, Eloise Scarano, Maria Colia, Pamela Ranghetti, Piera Angelillo, Paola Ronchi, Maurilio Ponzoni, Andrés J. M. Ferreri, Paolo Ghia
Journal: Blood Advances
Blood Adv (2022) 6 (18): 5356–5359.
https://doi.org/10.1182/bloodadvances.2022007138
Published: 2022
Includes: Supplemental data
Journal Articles

Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial

Clinical Trials & Observations
Andrés J. M. Ferreri, Teresa Calimeri, Maurilio Ponzoni, Flavio Curnis, Gian Marco Conte, Eloise Scarano, Eltjona Rrapaj, Daniela De Lorenzo, Dario Cattaneo, Federico Fallanca, Alessandro Nonis, Marco Foppoli, Paolo Lopedote, Giovanni Citterio, Letterio S. Politi, Marianna Sassone, Piera Angelillo, Elena Guggiari, Sara Steffanoni, Vittoria Tarantino, Fabio Ciceri, Claudio Bordignon, Nicoletta Anzalone, Angelo Corti
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3648–3658.
https://doi.org/10.1182/bloodadvances.2020002270
Published: 2020
Includes: Multimedia, Supplemental data